基于辨证的中成药在急性冠脉综合征PCI术后患者中的有效性与安全性:全国队列研究
这项全国前瞻性队列研究在40个中心纳入ACS行PCI术后患者,按是否接受辨证中成药(冠心丹参滴丸、芪参益气滴丸或丹蒌片)分为SDCPM组与CM组,随访36个月。结果显示SDCPM组主要终点和次要终点风险均低于CM组,SAQ评分更高,不良事件无显著差异。
要点
- ACS患者PCI术后在常规西药基础上加用辨证中成药可降低主要心血管事件风险。
- 辨证中成药还可降低再住院、心衰、卒中等次要终点风险并改善生活质量。
- 两组不良事件无显著差异,提示短期至中期用药安全性可接受。
核心结论
- ACS患者PCI术后在常规治疗基础上加用辨证中成药可降低主要和次要终点事件,并改善生活质量,且不增加不良事件。
研究设计与样本
- 全国前瞻性队列研究,在中国大陆40个中心开展,共2724例完成主要终点随访,其中SDCPM组1380例。
- 患者根据是否接受辨证中成药分为SDCPM组或CM组,随访时间36个月。
主要发现
- 中位随访541天(四分位距513-564天),主要终点在SDCPM组发生126例(8.61%),CM组167例(11.62%),校正HR=0.70(95%CI 0.55-0.89),p=0.003。
- 次要终点在SDCPM组发生144例(9.84%),CM组197例(13.71%),校正HR=0.66(95%CI 0.53-0.82),p<0.001。
- SAQ评分SDCPM组高于CM组(366.78±70.19 vs 356.43±73.80,p<0.001)。
- 两组不良事件无显著差异。
关键数值与推荐
- 主要终点由心源性死亡、非致死性心肌梗死和紧急血运重建组成。
- 次要终点包括因ACS再住院、心力衰竭、卒中及其他血栓事件。
- 辨证中成药包括冠心丹参滴丸、芪参益气滴丸或丹蒌片,按中医辨证对应使用。
临床怎么用
- 对ACS行PCI术后患者在常规西药治疗基础上,可考虑根据中医辨证加用相应中成药以降低心血管事件风险。
- 选择中成药时应遵循辨证论治原则,如冠心丹参滴丸、芪参益气滴丸或丹蒌片对应不同证型。
局限性
- 原文未报告局限性相关内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The incidence of cardiovascular events remains not unusual in patients following percutaneous coronary intervention (PCI) due to acute coronary syndrome (ACS). Chinese patent medicine (CPM) therapy based on syndrome differentiation in addition to conventional medicine (CM) had been expected to further reduce the risk of cardiovascular events. PURPOSE: To assess the effectiveness and safety of CPM based on syndrome differentiation in patients following PCI due to ACS. STUDY DESIGN: Nationwide prospective cohort study. METHODS: CPM study was conducted in 40 centers in mainland China. Patients following PCI due to ACS entered to syndrome differentiation-based CPM (SDCPM) or CM group according to whether they received CPM or not. The CPM comprised Guanxin Danshen dripping pills, Qishen Yiqi dripping pills, or Danlou tablets, and was used correspondingly with the syndrome differentiation of traditional Chinese medicine. The follow-up time was 36 months. The primary endpoint was composed of cardiac death, non-fatal myocardial infarction and urgent revascularization. The secondary endpoint included rehospitalization due to ACS, heart failure, stroke, other thrombotic events. Seattle Angina Questionnaire (SAQ) was used to evaluate quality of life. RESULTS: Between February 2012 and December 2018, ascertainment of the primary endpoint was completed in 2,724 patients of follow-up. 1,380 patients were in SDCPM group. At a median follow-up of 541 (interquartile range 513 - 564) days, the primary endpoint occurred in 126 (8.61%) patients in SDCPM group and 167 (11.62%) patients in CM group (adjusted hazard ratio [HR] = 0.70; [95% confidence interval [CI] 0.55 - 0.89]; p = 0.003). The secondary endpoint occurred in 144 (9.84%) patients in SDCPM group and 197 (13.71%) patients in CM group (adjusted HR = 0.66; [95% CI 0.53 - 0.82]; p < 0.001). The SAQ score in SDCPM group was higher than CM group (366.78 ± 70.19 vs 356.43 ± 73.80, p < 0.001). There were no significant differences of adverse events between two groups. CONCLUSION: In patients following PCI due to ACS, SDCPM in addition to CM treatment reduced the primary and secondary endpoints, as well as improved the quality of life without adverse events.
引用
- Bai R, Yang Q, Xi R, et al. The effectiveness and safety of Chinese Patent Medicines based on syndrome differentiation in patients following percutaneous coronary intervention due to acute coronary syndrome (CPM trial): A nationwide Cohort Study. Phytomedicine. 2022. PMID: 36610159. doi:10.1016/j.phymed.2022.154554
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。